V vs. GSK.L
V (Visa Inc.) and GSK.L (GlaxoSmithKline plc) are both stocks. V operates in Credit Services (Financial Services), while GSK.L operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, V returned 15.64%/yr vs 4.80%/yr for GSK.L. At a 0.21 correlation, their price movements are largely independent.
Performance
V vs. GSK.L - Performance Comparison
Loading charts...
Different Trading Currencies
V is traded in USD, while GSK.L is traded in GBp. To make them comparable, the GSK.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, V achieves a -8.47% return, which is significantly lower than GSK.L's 5.71% return. Over the past 10 years, V has outperformed GSK.L with an annualized return of 15.64%, while GSK.L has yielded a comparatively lower 4.80% annualized return.
V
- 1D
- -1.21%
- 1M
- 0.48%
- YTD
- -8.47%
- 6M
- -1.79%
- 1Y
- -12.97%
- 3Y*
- 13.52%
- 5Y*
- 7.39%
- 10Y*
- 15.64%
GSK.L
- 1D
- -1.24%
- 1M
- 2.51%
- YTD
- 5.71%
- 6M
- 7.01%
- 1Y
- 29.39%
- 3Y*
- 18.35%
- 5Y*
- 4.98%
- 10Y*
- 4.80%
V vs. GSK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
V Visa Inc. | -8.47% | 11.76% | 22.32% | 26.31% | -3.40% | -0.31% | 17.12% | 43.33% | 16.49% | 47.18% |
GSK.L GlaxoSmithKline plc | 5.71% | 52.14% | -5.11% | 10.47% | -33.85% | 25.52% | -18.33% | 30.34% | 12.28% | -2.33% |
Correlation
The correlation between V and GSK.L is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Mar 20, 2008 | 0.22 |
Fundamentals
V:
$15.24
GSK.L:
£1.42
V:
20.98
GSK.L:
13.43
V:
1.29
GSK.L:
0.30
V:
10.84
GSK.L:
2.39
V:
$43.03B
GSK.L:
£32.78B
V:
$16.94B
GSK.L:
£23.84B
V:
$27.63B
GSK.L:
£11.56B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
V vs. GSK.L — Risk / Return Rank
V
GSK.L
V vs. GSK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Visa Inc. (V) and GlaxoSmithKline plc (GSK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| V | GSK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.73 | ||
| Sortino ratioReturn per unit of downside risk | -2.49 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.21 | -0.30 |
| Calmar ratioReturn relative to maximum drawdown | -0.64 | 1.58 | -2.22 |
| Martin ratioReturn relative to average drawdown | -1.18 | 3.69 | -4.87 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| V | GSK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.58 | 1.15 | -1.73 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.33 | 0.20 | +0.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.64 | 0.21 | +0.43 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.69 | 0.15 | +0.53 |
Drawdowns
V vs. GSK.L - Drawdown Comparison
The maximum V drawdown since its inception was -51.90%, roughly equal to the maximum GSK.L drawdown of -51.16%. Use the drawdown chart below to compare losses from any high point for V and GSK.L.
Loading charts...
Drawdown Indicators
| V | GSK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -51.90% | -51.16% | -0.74% |
Max Drawdown (1Y)Largest decline over 1 year | -20.38% | -18.53% | -1.85% |
Max Drawdown (3Y)Largest decline over 3 years | -20.38% | -29.30% | +8.92% |
Max Drawdown (5Y)Largest decline over 5 years | -28.60% | -51.16% | +22.56% |
Max Drawdown (10Y)Largest decline over 10 years | -36.36% | -51.16% | +14.80% |
Current DrawdownCurrent decline from peak | -13.69% | -15.20% | +1.51% |
Average DrawdownAverage peak-to-trough decline | -8.26% | -15.96% | +7.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.03% | 7.93% | +3.10% |
Volatility
V vs. GSK.L - Volatility Comparison
Visa Inc. (V) and GlaxoSmithKline plc (GSK.L) have volatilities of 5.74% and 5.92%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| V | GSK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.74% | 5.92% | -0.18% |
Volatility (6M)Calculated over the trailing 6-month period | 17.50% | 18.51% | -1.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.32% | 25.56% | -3.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.80% | 24.76% | -1.96% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.47% | 22.99% | +1.48% |
Dividends
V vs. GSK.L - Dividend Comparison
V's dividend yield for the trailing twelve months is around 0.81%, less than GSK.L's 3.50% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 3.50% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
V Visa Inc. | 0.81% | 0.70% | 0.68% | 0.72% | 0.76% | 0.62% | 0.56% | 0.56% | 0.67% | 0.61% | 0.75% | 0.64% |
Financials
V vs. GSK.L - Financials Comparison
This section allows you to compare key financial metrics between Visa Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
V vs. GSK.L - Profitability Comparison
V - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported a gross profit of -8.90B and revenue of 11.23B. Therefore, the gross margin over that period was -79.3%.
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
V - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported an operating income of 7.23B and revenue of 11.23B, resulting in an operating margin of 64.4%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
V - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported a net income of 6.02B and revenue of 11.23B, resulting in a net margin of 53.6%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
V and GSK.L have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for V and GSK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer